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Abstract
The abuse of psychostimulants, such as methamphetamine (METH), is prevalent in young adults and could lead to long-
term adaptations in the midbrain dopamine system in abstinent human METH abusers. Nurr1 is a gene that is critical for the
survival and maintenance of dopaminergic neurons and has been implicated in dopaminergic neuron related disorders. In
this study, we examined the synergistic effects of repeated early exposure to methamphetamine in adolescence and
reduction in Nurr1 gene levels. METH binge exposure in adolescence led to greater damage in the nigrostrial dopaminergic
system when mice were exposed to METH binge later in life, suggesting a long-term adverse effect on the dopaminergic
system. Compared to naı ¨ve mice that received METH binge treatment for the first time, mice pretreated with METH in
adolescence showed a greater loss of tyrosine hydroxylase (TH) immunoreactivity in striatum, loss of THir fibers in the
substantia nigra reticulata (SNr) as well as decreased dopamine transporter (DAT) level and compromised DA clearance in
striatum. These effects were further exacerbated in Nurr1 heterozygous mice. Our data suggest that a prolonged adverse
effect exists following adolescent METH binge exposure which may lead to greater damage to the dopaminergic system
when exposed to repeated METH later in life. Furthermore, our data support that Nurr1 mutations or deficiency could be a
potential genetic predisposition which may lead to higher vulnerability in some individuals.
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Introduction
Nurr1 is one of the most important genes for the development
and maintenance of dopaminergic (DA-ergic) neurons. Loss of
Nurr1 gene during development leads to absence of midbrain
DAergic neurons [1]. Nurr1 is expressed throughout the
adulthood in mice [2]. It regulates several important genes that
are involved in the synthesis and metabolism of DA [3] as well
supports the survival of DAergic neurons [4]. A recent study [5]
indicated that reduction of Nurr1 function in adulthood leads to a
slowly progressive loss of striatal DA and markers for DAergic
neurons, supporting its selective roles in the maintenance of
DAergic neuronal survival and function. Deficiency in Nurr-1
expression results in a Parkinson’s disease (PD)-like phenotype. For
example, there were more DAergic neurons lost in the substantia
nigra compacta than in the ventral tegmental area when Nurr1
was deleted in maturing DAergic neurons [5]. Nurr1 heterozygous
mice, which have decreased Nurr1 mRNA and protein levels, are
more vulnerable to injury induced by the DAergic toxin (1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine) MPTP [6]. Furthermore,
Nurr1 expression is diminished in neurons with alpha-synuclein
inclusions in postmortem PD brain tissue [7]; Nurr1 mutations and
polymorphisms have also been identified in rare cases of PD
[7,8,9,10]. Taken together, these data suggest that deficiency in
Nurr1 expression may enhance susceptibility to neuronal damage
in DAergic neurons, which leads to PD- like symptoms in animals
or man.
Methamphetamine (METH) is a commonly abused drug and
DAergic neurotoxin. METH causes damage to nigrostriatal
DAergic neurons as evidenced by marked decreases in the
neostriatal content of DA and activity of tyrosine hydroxylase
(TH) [11,12,13]. METH selectively injures the neurites of DA
neurons, generally without inducing cell death [14]. Administra-
tion of METH also enhanced nNOS (neuronal nitric oxide
synthase) and 3-nitrotyrosine level in the striatum. These Meth-
associated neurodegenerative effects were further potentiated in
Nurr1 heterozygous mice [15].
The purpose of this study was to examine the long term effect of
repeated methamphetamine exposure in Nurr1 deficient hetero-
zygous mice. Our data suggest that repeated METH binge
exposure lead to greater damage in DA neurons and that a
deficiency in Nurr1 expression further potentiates METH toxicity.
Materials and Methods
Animals and drug administration
The use of animals was conducted under National Institutes
Health (NIH) Guidelines using the NIH handbook Animals in
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Use Committee (National Institute on Drug Abuse, Intramural
Research Program, Baltimore, MD), approval ID 07-CNRB-61.
Young adult (6–8 weeks) male heterozygous Nurr1 mice (Nurr1
+/2), originally generated by Dr. Thomas Perlmann [1], and
their littermate wild-type controls (+/+), were bred at NIDA. All
animals were genotyped as previously described [1]. Animals were
separated into 3 groups. (A) Single binged group (1XMETH):
Animals received saline injections at 6–8 weeks old and received
binge injections (10 mg/kg, x4, every 2 hours, s.c.) 5 months later.
(B) Double binged group (2XMETH): Animals received binge
injections (10 mg/kg, x4, every 2 hours, s.c.) at 6–8 weeks old and
received a second binge (10 mg/kg, x4, every 2 hours, s.c.) 5
month later. (C) Control group: Animals received saline injections
(0.01 ml/10 g, x4, every 2 hours, s.c.) at 6–8 weeks old, repeated 5
months later. During the injection period, animals were housed
individually without bedding.
TH immunostaining
Animals were anesthetized and perfused transcardially with
saline followed by 4% paraformaldehyde (PFA) in phosphate
buffer (PB; 0.1 M; pH 7.2) on the 4
th day after METH injections.
The brains were dissected, postfixed in PFA for 16 hours, and
transferred to 18% sucrose in 0.1 M PB for at least 16 hours.
Serial sections of the entire brain were cut at 25 mm thickness in a
cryostat. One series from every 4th section was stained for each
antibody used. In order to control for staining variability,
specimens from all experimental groups were included in every
batch and reacted together in a net well tray under the same
conditions. Sections were rinsed in 0.1 M phosphate buffer, and
blocked with 4% bovine serum albumin (BSA) and 0.3% Triton x-
100 in 0.1 M PB. Sections were then incubated in a primary
antibody solution rabbit anti-TH (Chemicon, Temecula, CA) or
rat anti-DAT (Chemicon, Temecula, CA) diluted (1:500) in 4%
BSA and 0.3% Triton x-100 in 0.1 M PB for 24 hours at 4uC.
Sections were rinsed in 0.1 M PB and incubated in biotinylated
goat anti-rabbit IgG for TH or anti-rat IgG for DAT in the buffer
(1:200; Vector Laboratories, Burlingame CA) for 1 hour, followed
by incubation for 1 hour with avidin-biotin-horseradish peroxi-
dase complex. Staining was developed with 2,39 diaminobenzidine
tetrahydrochloride (0.5 mg/mL in 50 mM Tris-HCl buffer 7.4).
Control sections were incubated without primary antibody.
Sections were mounted on slides, and cover slipped. Histological
images were acquired using an Infinity3 camera and NIKON 80i
microscope. TH and DAT immunoreactivity in striatum was
visualized with the use of a Nikon super-coolscan 9000 scanner.
The optical density of TH and DAT immunoreactivity in
striatum was analyzed using Scion Image (ver 4.02) and averaged
from 3 sections with a visualized anterior commissure (AP:
+0.26 mm, +0.14 mm, +0.02 mm to bregma). TH fiber optical
density in substantia nigra pars reticulata (SNpr) and TH neuronal
density in substantia nigra pars compacta (SNpc) were quantified
by Nikon NIS-Elements software and averaged from 3 sections
(AP:23.28 mm, 23.40 mm, 23.52 mm to bregma). TH optical
density and TH neuron counts from right and left hemispheres
were averaged in each mouse for statistical analysis. All
immunohistochemical measurements were done by blinded
observers.
Quantitative reverse transcription-PCR (qRT-PCR)
Mice were euthanized and the brains were immediately
harvested and chilled on ice. The SN was dissected out and total
RNA was extracted following the instructions from the manufac-
turer (RNAqueous, Ambion). Total RNA (1 mg) was treated with
RQ-1 Rnase-free Dnase I and reverse transcribed into cDNA
using random hexamers by AMV reverse transcriptase (Roche).
cDNA levels for HPRT1 (hypoxanthine phosphoribosyltransferase
1), Hmbs (hydroxymethylbilane synthase) and Nurr1 were
determined using specific universal probe Library primer probe
sets (Roche) by quantitative RT-PCR. For each sample, duplicates
were measured in real-time PCR and the results were repeated at
least once with similar results. Primers and FAM-labeled probes
used in the quantitative RT-PCR for each gene are as follows:
HPRT: forward primer (59 –tgatagatccattcctatgactgtaga);
reverse primer (59 –aagacattctttccagttaaagttgag);
probe (mouse universal probeLibrary probe #22, Roche)
Hmbs : forward primer (59 – tccctgaaggatgtgcctac);
reverse primer (59-acaagggttttcccgtttg);
probe (mouse universal probeLibrary probe #79, Roche)
Nurr1 : forward primer (59 – tcagagcccacgtcgatt);
reverse primer (59- tagtcagggtttgcctggaa);
probe (mouse universal probeLibrary probe #64, Roche)
Figure 1. Nurr1 mRNA levels are decreased in the brains of
Nurr1 heterozygous mice. Substantia Nigra (SN) mRNA levels for
Nurr1, HPRT1 and Hmbs were measured in adult Nurr1 +/+ (n=5) and
+/2 mice (n=5) by qRT-PCR. Two housekeeping genes (HPRT1 and
Hmbs) did not differ between +/+ and +/2 mice (panel A). For each
sample, Nurr1 mRNA levels were normalized to the housekeeping gene
Hmbs mRNA levels. Nurr1 mRNA levels are significantly decreased (66%
of wildtype) in +/2 mice compared to levels in +/+ mice (**p,0.005,
Student’s t-test).
doi:10.1371/journal.pone.0015193.g001
Adolescent Exposure to Methamphetamine
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DA clearance in striatum was measured at 3 days after METH
or saline injections. Animals were anesthetized using urethane
(1.25 g/kg, i.p.). In-vivo chronoamperometric measurements of
extracellular dopamine (DA) concentration were performed as
previously described (Zhou et al. 1996). The recordings were taken
at rates of 10 Hz continuously using Nafion-coated carbon-fiber
working electrodes (tip=30 mm; SF1A, Quanteon, Lexington,
Kentucky) and a microcomputer-controlled apparatus (FAST
system, Quanteon). The clearance of DA was measured by
changes in extracellular DA concentration after microinjection of
DA into the striatal parenchyma (AP:0–0.5 mm and Lat 1.5 mm
from Bregma, DV 1.5–3.5 mm from brain surface). DA (,20
pmole in 100 uM solution) was locally applied through a
micropipette. The working electrode and the micropipette were
mounted together with sticky wax; tips were separated by 150 mm.
The electrode/pipette assembly was lowered into striatum (AP 0–
0.5 mm, M/L 2.0 mm relative to bregma and 1.5 to 3.5 mm
below the dura). Local application of DA from the micropipette
was performed by pressure ejection using a pneumatic pump
(BH2, Medical System). The ejected volume was monitored by
recording the change in the fluid meniscus in the pipette before
and after ejection using a dissection microscope.
Stereologic Analysis
Unbiased stereological counts of TH-positive (TH+) neurons
within the substantia nigra pas compacta (SNpc) were performed
using stereological principles and analyzed with StereoInvestigator
software (Microbrightfield, Williston, VT). Optical fractionator
sampling [16] was carried out on a Leica DM5000B microscope
(Leica Microsystems, Bannockburn, IL) equipped with a motor-
ized stage and Lucivid attachment (40X objective). Midbrain
dopaminergic groups were outlined on the basis of TH
immunolabeling, with reference to a coronal atlas of the mouse
brain (Franklin and Paxinos, [17]). For each tissue section
analyzed, section thickness was assessed in each sampling site
and guard zones of 2.5 mm were used at the top and bottom of
each section. Pilot studies were used to determine suitable
counting frame and sampling grid dimensions prior to counting.
The following stereolgic parameters were used in the final study:
grid size, (X) 220 mm, (Y) 166 mm; Counting frame, (X) 68.2 mm,
(Y) 75 mm, depth was 20 mm. Gundersen coefficients of error for
m=1 were all less than 0.10. Stereologic estimations were
performed with the same parameters in the SNpc of wildtype or
Nurr1 heterozygous mice that received saline, 1XMETH or
2XMETH treatment (n=6) for each treatment group.
Results
Nurr1 mRNA levels are decreased in heterozygous (+/2)
mice
We measured Nurr1 and housekeeping genes HPRT1 and
Hmbs mRNA levels in substantia nigra of Nurr1 +/2 and +/+
mice using quantitative real-time RT-PCR. There was no
difference between the +/2 (n=5) and +/+ (n=5) for both
housekeeping genes HPRT1 and Hmbs (Figure 1A). In contrast,
there was a 34% reduction of Nurr1 mRNA levels in Nurr1 +/2,
compared to +/+ mice (p,0.005, Student’s t-test). These data
suggest that the expression of Nurr1 was significantly reduced in
+/2 mice.
Loss of striatal TH immunoreactivity (THir) after single or
double binge METH injection
Animals were subjected to saline, a single binge (1XMETH) or
double binge exposure (2XMETH) as illustrated in Fig 2. A total
of 40 mice were sacrificed on the 4
th day after the last METH or
saline injection. No difference in THir (optical density) was found
between Nurr1 +/2 (n=6) and +/+ (n=6) mice after saline
injection (Fig 3A, B saline group, p=0.858 Two-way ANOVA,
post hoc Newman-Keuls test). 1XMETH significantly reduced
THir density in striatum in both Nurr1 +/+ (n=6) and +/2 mice
(n=6) (p,0.001, Two-way ANOVA, post hoc Newman-Keuls
test); however, the loss of THir optical density was more
prominent in Nurr1 +/2 mice (p,0.001, Two-way ANOVA,
post hoc Newman-Keuls test) suggesting an increased vulnerability
in these animals. Moreover, animals receiving double, comparing
to single, METH binge showed a much greater loss of THir in
striatum (Fig. 3A,B, p,0.001, Two-way ANOVA, post hoc
Newman-Keuls test). There was no difference between the +/+
(n=8) and +/2 (n=8) animals after 2XMETH; both genotypes
lost about 70% of the THir in striatum (p=0,317, Two-way
ANOVA, post hoc Newman-Keuls test). In summary, we found
that METH treatment significantly decreases THir in striatum
(Two-way ANOVA, treatment, F2, 77=189.410, p,0.001) and
Nurr1 +/2 showed a significantly exacerbated loss in THir in
stratium (Two-way ANOVA, genotype, F2, 77=6.771, p=0.011).
Figure 2. Treatment groups and schedules. Each group contained both Nurr1 +/+ and +/2 mice. Saline group mice received saline injections
when they were 6–8 weeks old and 5 months later. 1XMETH group mice received saline injections when they were 6–8 weeks old and received
1XMETH binge treatment (4X10 mg/kg) 5 months later. 2XMETH group mice received METH binge treatment (4X10 mg/kg) at both time points.
doi:10.1371/journal.pone.0015193.g002
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genotype (Two-way ANOVA, genotype x treatment, F2,77=3.916,
p=0.024).
Loss of SNpr THir fibers after single or double binge
METH injection
We next examined the effect of METH binge exposure on the
substantia nigra (SN). To evaluate DAergic neuron number in SN,
we performed unbiased stereological counts in various animal
groups. This unbiased method of cell counting is not affected by
either the volume of reference (SNpc) or the size of the counted
elements (neurons) [16]. The results showed that decreased level of
Nurr1 in heterozygous mice did not affect the number of
dopaminergic neurons in adult control mice (saline group,
wt =13714; het =13194, p=0.957, F(1,17)=0.003, Two-way
ANOVA). Furthermore, neither 1XMETH nor 2XMETH led to
Figure 3. Nurr1 +/2 mice exhibit greater reduction of striatal TH-immunoreactivity following METH exposure. (A) METH injection
reduced THir in +/+ and +/2 mice following one time binge METH exposure (1X METH) and repeated binge METH exposure (2XMETH).
Calibration=2 mm. (B) Quantitative THir fiber density analysis indicated that binge METH treatment significantly reduces THir in striatum and
2XMETH induced a further reduction of the THir in both +/+ and +/2 mice. There is a significant difference between saline and 1XMETH group
(p,0.001, Two-way ANOVA) and between 1XMETH and 2XMETH group (p,0.001, Two-way ANOVA) in striatal THir. In addition, there is also a
significant difference (p,0.001) between +/+ and +/2 mice after 1XMETH injection.
doi:10.1371/journal.pone.0015193.g003
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genotypes (p=0.556, F(2,17)=0.617, Two-way ANOVA; Fig 4).
TH fiber density in SNpr was analyzed using fiber density of THir.
1XMETH significantly reduced density of TH fibers in SNpr
(Two-way ANOVA, treatment p,0.001, F(2,48)=98.444;
p,0.001, post hoc Newman-Keuls test; Fig 5A, B) in both Nurr1
+/+ (n=10) and +/2 (n=10) mice; Nurr1 +/2 mice showed a
trend towards greater decrease in THir in SNpr (Two-way
ANOVA, p=0.058, post hoc Newman-Keuls test). 2XMETH
caused a further reduction in TH fiber density in SNpr in both
Nurr1 +/+ (n=8) and +/2 (n=7) animals (Two-way ANOVA,
p,0.001, post hoc Newman-Keuls test). Moreover, 2XMETH
caused a greater reduction of TH immunoreactivity in SNpr in
Nurr1 +/2, compared to +/+ mice (Two-way ANOVA,
p=0.028, post hoc Newman-Keuls test, Fig 5A, B). In summary,
METH treatment significantly decreases THir in SNpr (Two-way
ANOVA, treatment, F2, 48=98.444, p,0.001) and there is a
significant treatment-dependent difference between +/2 and +/+
mice (Two-way ANOVA, genotype x treatment, F2,48=5.692,
p=0.006). Taken together, these histological findings suggest that
Nurr1 +/2 mice are more sensitive to METH –mediated damage
in DAergic neurites.
Electrochemical measurement of dopamine clearance in
Nurr1 +/+ and +/2 mice after single or double binge
METH injection
DA clearance was examined after local application into the
striatum in 23 mice at 3 days after the last injection of METH
or saline. Extracellular DA levels were recorded in 136 striatal
sites between 1.5 mm to 3.5 mm below the brain surface. Of
these, 72 sites were taken from Nurr1 +/2 mice while 64 sites
were recorded from wt (+/+)m i c e .L o c a la p p l i c a t i o no fD A
(10.2 +/2 0.6 pmole/site) induced an increase in extracellular
DA levels. Previous chronoamperometric studies have shown a
dose-dependant relationship between the peak of extracellular
DA and log dose of applied DA through a micropipette in rat
striatum [18]. In this study, the amplitude of DA release was
also normalized by comparison to the log of dose used (in
pmole). We found that extracellular DA concentration was
significantly enhanced after local DA application in Nurr1
+/2 mice (F1,145=13.488, p,0.001, two way ANOVA). A
significant decrease in clearance was found in Nurr+/2 mice
after 2XMETH treatment (Fig 6, p=0.010, post-hoc New-
man-Keuls test). No significant difference was found after
1XMETH (p=0.126) or saline treatment (p=0.118). These
data suggest that 2XMETH reduced DA clearance in Nurr1
+/2 mice.
Examination of striatal DAT immunoreactivity (DATir)
after single or double binge METH injection
To examine whether the reduced DA reuptake is due to loss of
DAT protein in striatum, we examined the level of DATir by
optical density in striatum in saline and METH -exposed (+/+)
and (+/2) animals. No difference in DATir (optical density) was
found between Nurr1 +/2 (n=6) and +/+ (n=6) mice after saline
injection (Fig 7A, B saline group, p=0.127, Two-way ANOVA,
post hoc Newman-Keuls test). Consistent with the in vivo
electrochemistry data, we found that 1XMETH significantly
reduced DATir in both Nurr1 +/+ (n=6) and +/2 mice (n=6)
(Fig 7A, Two-way ANOVA, p,0.001, post hoc Newman-Keuls
test). No significant difference was found between these two
genotypes (Fig 7B, panel 2, Two-way ANOVA, p=0.681, post
hoc Newman-Keuls test). In contrast, following 2XMETH, there
was a significant reduction of DAT optical density in Nurr1 +/2
(n=10), compared to +/+ mice (n=10) (Fig 7A, B, Two-way
ANOVA, p,0.001, post hoc Newman-Keuls test Statistics). In
Figure 4. Stereological counts of SNpc TH-positive DAergic neuron numbers. DAergic neuron numbers in Nurr1 +/+ and +/2 mice treated
with saline, 1XMETH and 2XMETH were estimated using unbiased stereologic principles. METH binge treatment does not lead to loss of
dopaminergic neurons in SNpc (p=0.556, F(2,17)=0.617, Two-way ANOVA). Furthermore, there is no difference between wt and heterozygous mice
(p=0.957, F(1,17)=0.003, Two-way ANOVA).
doi:10.1371/journal.pone.0015193.g004
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the DATir in striatum (Two-way ANOVA, treatment, F2,
82=882.560, p,0.001) and Nurr1 +/2 showed a significant
exacerbated loss in DATir in striatum after 2XMETH (Two-way
ANOVA, p,0.001). There is a significant interaction between the
treatment and genotype (Two-way ANOVA, genotype x treat-
ment, F2, 82=4.483, p=0.014). Taken together, the immunohis-
tochemical measurements on DAT density correlate well with the
Figure 5. Nurr1 +/2 mice exhibit decreased TH-immunoreactivity in SNpr following methamphetamine exposure. (A) TH
immunostaining indicates that METH administration augments the reduction in THir in the SNpr of Nurr1 +/2, compared to +/+ mice following
repeated METH binge treatment. Calibration bar=500 um. (B) THir fiber density analysis indicated METH treatment (1xMETH) reduced THir fiber
density in SNpr in +/+ and +/2 mice (p,0.001, Two-way ANOVA) and repeated METH binge treatment (2XMETH) further reduced THir fiber density in
SNpr (p,0.001, Two-way ANOVA). A trend of greater reduction in TH immunoreactivity was found in the Nurr1 +/2 mice following 1XMETH
(p=0.058, Two-way ANOVA, post hoc Newman-Keuls test) and a significant decrease in THir in SNpr was found in Nurr1 +/2 mice following repeated
METH treatment (2XMETH). (p,0.05, Two-way ANOVA, post hoc Newman-Keuls test).
doi:10.1371/journal.pone.0015193.g005
Adolescent Exposure to Methamphetamine
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decreased DA clearance in Nurr1 (+/2) mice after 2XMETH
could be due to an elevated loss of DAT protein in the neuronal
terminals.
Discussion
Previous studies have indicated that the nigrostriatal DA
pathway is vulnerable to the toxic effect of METH. High doses
of METH increase extracellular concentration of DA, DA
metabolites, and glutamate in the nigrostriatal terminal fields in
vivo [19,20]. These toxic metabolites/compounds may contribute
to the acute toxicity of METH at the DAergic terminals. In this
study, we demonstrated that repeated exposure to high doses of
METH caused further neurodegeneration in the nigrostriatal
DAergic pathway. We found that METH binge, given at early life
(week 6–8 in mice), potentiated the reduction of TH and DAT
immunoreactivity in striatum and nigra after a second METH
binge, given at 5 month later, a long time effect which has not
been reported previously. These data also suggest that after the
initial METH binge, subsequent adult exposure increases METH
toxicity.
We also demonstrated the interaction of METH and Nurr1 in
the nigrostriatal DAergic pathway. There is a further reduction of
TH or DAT as well as DA clearance in Nurr-1 (+/2) mice after
repeated treatment with high doses of METH, suggesting a
synergistic neurodegenerative response between deficiency in
Nurr1 and repeated METH exposure in DAergic neurons. The
biological mechanisms for this interaction have not been clearly
identified. It has been shown that Nurr1 +/2 mice had an
elevated nNOS and nitration in striatum [15]. Deficiency in Nurr1
has also been suggested to play a role in the induction of
apoptosomes via NO. Furthermore, Nurr1+/2 mice had an
elevated p53 protein level as well as an increased Cytochrome C
levels in the striatum after a single METH binge treatment [15].
All these toxic responses may result in the greater loss of THir and
DATir in these animals as shown in our study. Since DA clearance
and DAT expression in striatum were reduced in +/2 mice after
repeated METH binge treatment, it is also possible that the
overflow of DA in these animals further potentiates damages to
DAergic neurons after METH treatment. Decreased DA clear-
ance might also account for the elevated locomotor activity
observed in Nurr1 +/2 mice compared to +/+ after METH
administration as previously reported by our group [21].
A recent study from Cadet et al [22] demonstrated a precondi-
tioning protective effect of METH on subsequent METH binge
exposure if the pretreatment of METH was given at lower doses over
a longer period of time. The differential effects of METH
pretreatment on the subsequent exposure might be due to different
regimens of drug administration. While chronic low dose pretreat-
ment could induce certain protective genes such as SOD (Superoxide
Dismutase) and trophic factors [22], high dose METH binge
treatment leads to downregulation of trophic factors [23] and anti-
apoptotic genes such as bcl-2 [15]. In contrast to the protective effect
of low dose chronic preconditioning, our results suggest that
intermittent binge exposure causes detrimental instead of protective
effects on subsequent METH exposure. To further define mecha-
nisms on how difference in Nurr1 expression affects methamphet-
amine vulnerability, given data from Cadets lab [22] on apoptosis
and trophic factor changes, we also utilized RTPCR to study
expression of apoptotic genes (Bcl2/BAX) as well as trophic factors
(BDNF, SHH). We found no significant changes between groups,
suggesting other mechanisms may be involved (data not shown).
Therefore, the elevated vulnerability of Nurr1 +/2 mice to repeated
M E T Ht r e a t m e n ti sa tl e a s tn o tm e d i a t e db yt h eB c l 2 / B a xp a t h w a y .
This speculation is consistent with our results showing that there is no
actual DAergic cell loss in SNpc after METH binge treatment.
Previous studies have demonstrated that the suppression of
KCl-mediated DA release is reversible 1 to 6 months after high
dose METH administration in adult Fisher rats [24], suggesting a
transient suppression of certain DAergic phenotypes and sponta-
neous recovery of DA release function after acute METH
treatment in rodents. Consistent with previous reports, using
unbiased stereological counts of SNpc DAergic neuron number,
we did not observe a loss of dopaminergic neurons in SNpc in
METH binge treated animals. Most of the acute toxicity observed,
including suppressed locomotor activity, loss of THir fibers in
striatum and loss of THir projections in SNr, recover in 2–4 weeks
after the METH binge exposure (data not shown). However, we
also found a long term neurodegenerative effect in DAergic
neuronal terminals after METH binge treatment in animals with a
deficiency in Nurr1 expression. Since Nurr1 is essential for the
survival and function of doapminergic neurons [5], it is possible
that Nurr1 may be involved in the spontaneous recovery after
METH exposure. Deficiency in Nurr1 expression levels in +/2
mice may lead to a compromised functional recovery. Small
molecules that could upregulate Nurr1 activity might thus be a
therapeutic target for METH toxicity and PD.
It has been shown that newborn Nurr1 +/2 mice have
significantly reduced levels of Nurr1 protein and DA in the
striatum [1], indicating that nigrostriatal DA levels are affected by
Nurr1 mRNA dosage. Moreover, in adulthood, these heterozy-
gous mice showed increased vulnerability to the neurotoxin MPTP
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) compared to their
wildtype littermates [6]. Similarly, DAergic trophic factors have
been reported to alter DAergic function after METH exposure. It
has been reported that deficiency in GDNF (Glial cell line-derived
neurotrophic factor) level leads to a greater vulnerability to
METH binge exposure in GDNF +/2 mice [25]. We have also
reported that reduced BMP7 (Bone morphogenetic protein 7)
levels in BMP7 +/2 mice caused a larger adverse effect by METH
binge treatment [23]. Whether there is a common mechanism for
these trophic factors in protecting DA neurons from METH
exposure requires further investigation.
Figure 6. Further reduction of DA clearance in the striatum
after repeated METH binge in Nurr-1 +/2 mice. Extracellular DA
concentration was measured using chronoamperometry after local
application of low doses (10.2+/20.6 pmole/site) of DA through
micropipettes in mouse striatum after saline, 1xMETH or 2XMETH
treatment. Amplitude of DA signals was normalized by comparison to
the log of dose used. Extracellular DA concentration was significantly
enhanced in Nurr1 +/2, compared to +/+ mice, after 2XMETH treatment
(*, p,0.05, Two-way ANOVA, post hoc Newman-Keuls test).
doi:10.1371/journal.pone.0015193.g006
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15193Figure 7. Decreased DA clearance due to loss of DAT expression in striatum. (A) DAT immunostaining indicates that METH administration
augments the reduction in DATir in the striatum of Nurr1 +/2, compared to +/+ mice following repeated METH binge treatment. Calibration
bar=2 mm. (B) DATir fiber density analysis indicated METH treatment (1xMETH) reduced DATir fiber density in striatum in +/+ and +/2 mice
(p,0.001, Two-way ANOVA) and repeated METH binge treatment (2XMETH) further reduced DATir fiber density in striatum in Nurr1 +/2 mice
compared to +/+ mice (p,0.001, Two-way ANOVA). Nurr1 +/2 mice showed decreased DATir after 2X METH treatment compared to +/+ animals, but
not in saline-treated or 1XMETH-treated groups, a result consistent with decreased DA clearance in 2XMETH-treated Nurr1 +/2 mice. ** indicates that
there is a significant difference between the treatment (p,0.001, Two-way ANOVA) and ## indicates that there is significant difference between the
genotypes after 2XMETH treatment (p,0.001, Two-way ANOVA).
doi:10.1371/journal.pone.0015193.g007
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adulthood leads to long term effects in the nigrostriatal system
and results in a more marked dysfunction when animals are
exposed to METH again later in life. This adverse effect is
further exacerbated in mice that have a decreased level of
Nurr1. Therefore, lowered Nurr1 levels may predispose
individuals to greater acute and/or long term toxicity of
METH in the nervous system. Our data suggest that METH
b i n g ee x p o s u r ei ne a r l yl i f ec a ne x a c e r b a t en e u r o d e g e n e r a t i o n
induced by a 2
nd METH exposure, especially in Nurr-1
d e f i c i e n ta n i m a l s .I ti sp o s s i b l et h a tm u t a t i o n so rp o l y m o r -
phisms in the Nurr1 gene in humans, which lead to lower levels
of Nurr1 expression, may predispose certain individuals to
greater susceptibility to neuronal disorders or greater suscep-
tibility to neurotoxicants after repeated exposure. Small
molecules that can regulate Nurr1 function and activity might
be a candidate medications development target for METH
toxicity and PD.
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